Viral proteases are critical enzymes for the maturation of many human pathogenic viruses
and thus are key targets for direct acting antivirals (DAAs). The current viral pandemic …

New variants of the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)
emerged and spread rapidly all over the world, which strongly supports the need for …

The high mutation rate of COVID-19 and the prevalence of multiple variants strongly support
the need for pharmacological options to complement vaccine strategies. One region that …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in
the current COVID-19 pandemic. Worldwide this disease has infected over 2.5 million …

SARS-CoV-2 main protease (Mpro) is a cysteine protease that mediates the cleavage of
viral polyproteins and is a validated antiviral drug target. Mpro is highly conserved among all …

The ongoing spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has
caused hundreds of millions of cases and millions of victims worldwide with serious …

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The viral outbreak started in late 2019 and rapidly became a …

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), which causes coronavirus
disease 2019 (COVID-19), threatens global public health. The world needs rapid …

The rapid outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) in China followed by its spread around the world poses a serious global concern for …

The COVID-19 pandemic caused by the SARS-CoV-2 requires a fast development of
antiviral drugs. SARS-CoV-2 viral main protease (Mpro, also called 3C‐like protease …